The Phase 2 success significantly de-risks RAP-219's bipolar mania program and validates the TARPγ8 mechanism. Key catalysts to watch: End-of-Phase 2 FDA meeting in Q1 2027, Phase 3 initiation in 2H 2027, and upcoming FOS open-label safety data in Q4 2026. Monitor for potential partnership interest given the broad pipeline-in-a-product potential.
Price Chart
Executive Summary
Rapport Therapeutics announced positive topline Phase 2 results for RAP-219 in acute bipolar mania, meeting the primary endpoint (3.1-point YMRS improvement vs placebo, p=0.045) and secondary endpoint (CGI-BP-S mania, p=0.024) with a well-tolerated safety profile. The data establish clinical proof-of-concept for this novel TARPγ8-selective mechanism, supporting progression to Phase 3 trials expected in 2H 2027. The company also provided a pipeline update and confirmed $436.1M cash runway into 2H 2029.
Key Facts
- Phase 2 trial met primary endpoint: 3.1-point placebo-adjusted YMRS improvement at Week 3 (p=0.045)
- RAP-219 patients had 15.4-point mean YMRS reduction from baseline vs 12.3 for placebo
- Secondary endpoint met: 0.4-point CGI-BP-S mania improvement (p=0.024)
- No SAEs; all TEAEs mild/moderate; discontinuation due to AEs 3.2% RAP-219 vs 0.8% placebo
- 253 patients enrolled in randomized, double-blind, placebo-controlled US trial
- End-of-Phase 2 FDA meeting expected Q1 2027; Phase 3 initiation expected 2H 2027
- Cash position $436.1M as of June 30, 2026, expected to fund operations into 2H 2029
Financial Impact
Positive Phase 2 data de-risks RAP-219 in bipolar mania, a multibillion-dollar market opportunity; $436.1M cash runway supports Phase 3 programs across epilepsy and bipolar mania
Risk Factors
- Phase 3 trials may fail to replicate Phase 2 efficacy or safety results
- Regulatory pathway and Phase 3 design subject to FDA feedback in Q1 2027
- Higher discontinuation rate on RAP-219 (24.6%) vs placebo (11.8%), primarily due to withdrawal of consent
- Competition from existing and novel bipolar mania treatments
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-425647 |
| Document: d185134dex991.htm | 0001193125-26-425647 |
| Document: d185134dex992.htm | 0001193125-26-425647 |
| Document: 0001193125-26-425647-index-headers.html | 0001193125-26-425647 |
| Document: 0001193125-26-425647-index.html | 0001193125-26-425647 |
| Document: 0001193125-26-425647.txt | 0001193125-26-425647 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 23, 2026 2d ago | Insider Cluster | $26.00 | awaiting T+5 | — | $25.93 (−0.27%) |
Oct 22, 2026 4d ago | Insider Cluster | $27.33 | awaiting T+5 | — | $25.93 (−5.12%) |
Oct 21, 2026 4d ago | Insider Buy | $26.53 | awaiting T+5 | — | $25.93 (−2.26%) |
Oct 20, 2026 6d ago | 8-K | $29.37 | awaiting T+5 | — | $25.93 (−11.71%) |
Oct 6, 2026 19d ago | 144 | $30.86 $28.33 | ▲ +8.20% | ▲ +7.22% | $25.93 (+15.98%) |
Oct 1, 2026 24d ago | Insider Cluster | $32.17 $30.65 | ▼ −4.72% | ▼ −5.89% | $25.93 (−19.40%) |
Aug 26, 2026 8w ago | Insider Cluster | $50.83 $47.65 | ▼ −6.26% | ▼ −6.52% | $25.93 (−48.99%) |
Aug 5, 2026 11w ago | 8-K | $42.44 $47.73 | ▲ +12.46% | ▲ +12.11% | $25.93 (−38.90%) |
Jul 1, 2026 16w ago | Insider Cluster | $38.97 $41.75 | ▲ +7.13% | ▲ +5.77% | $25.93 (−33.46%) |
Jun 30, 2026 16w ago | 144 | $39.39 $39.72 | ▲ +0.84% | ▲ +0.58% | $25.93 (−34.17%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers